- Home
- CGTX vs RADX Comparison
CGTX vs RADX Comparison
Compare CGTX & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- RADX
- Stock Information
- Founded
- CGTX 2007
- RADX 2021
- Country
- CGTX United States
- RADX Australia
- Employees
- CGTX N/A
- RADX N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- CGTX Health Care
- RADX
- Exchange
- CGTX Nasdaq
- RADX NYSE
- Market Cap
- CGTX 26.8M
- RADX 31.8M
- IPO Year
- CGTX 2021
- RADX N/A
- Fundamental
- Price
- CGTX $0.37
- RADX $4.30
- Analyst Decision
- CGTX Strong Buy
- RADX Strong Buy
- Analyst Count
- CGTX 5
- RADX 1
- Target Price
- CGTX $7.13
- RADX $15.00
- AVG Volume (30 Days)
- CGTX 595.7K
- RADX 39.3K
- Earning Date
- CGTX 05-06-2025
- RADX 02-26-2025
- Dividend Yield
- CGTX N/A
- RADX N/A
- EPS Growth
- CGTX N/A
- RADX N/A
- EPS
- CGTX N/A
- RADX N/A
- Revenue
- CGTX N/A
- RADX $204,609.00
- Revenue This Year
- CGTX N/A
- RADX N/A
- Revenue Next Year
- CGTX N/A
- RADX N/A
- P/E Ratio
- CGTX N/A
- RADX N/A
- Revenue Growth
- CGTX N/A
- RADX N/A
- 52 Week Low
- CGTX $0.31
- RADX $3.50
- 52 Week High
- CGTX $2.95
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- CGTX 43.16
- RADX N/A
- Support Level
- CGTX $0.31
- RADX N/A
- Resistance Level
- CGTX $0.41
- RADX N/A
- Average True Range (ATR)
- CGTX 0.04
- RADX 0.00
- MACD
- CGTX 0.01
- RADX 0.00
- Stochastic Oscillator
- CGTX 51.85
- RADX 0.00
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.